Comparison
46 Xx Disorder Of Sex Development Induced By Maternal Derived Androgen C5680197 vs 3q13 Microdeletion Syndrome C2931338
Clinical comparison between 46 XX Disorder OF Sex Development Induced BY Maternal Derived Androgen and 3q13 Microdeletion Syndrome for differential diagnosis and treatment planning.
46 Xx Disorder Of Sex Development Induced By Maternal Derived Androgen C5680197
A condition where androgens from the pregnant person cross to the fetus, causing atypical genital development in an XX baby. It ranges from mild to severe. Specialists guide hormone and surgical management.
3q13 Microdeletion Syndrome C2931338
A genetic disorder from missing material on chromosome 3q13, associated with developmental delays, intellectual disability, and various congenital features.
6 comparison axes
Onset
46 Xx Disorder Of Sex Development Induced By Maternal Derived Androgen C5680197
0-0
3q13 Microdeletion Syndrome C2931338
Variable
Onset patterns differ
Severity
46 Xx Disorder Of Sex Development Induced By Maternal Derived Androgen C5680197
severe
3q13 Microdeletion Syndrome C2931338
moderate
Different severity levels
Chronic
46 Xx Disorder Of Sex Development Induced By Maternal Derived Androgen C5680197
Chronic
3q13 Microdeletion Syndrome C2931338
Chronic
Differing course
Communicable
46 Xx Disorder Of Sex Development Induced By Maternal Derived Androgen C5680197
No
3q13 Microdeletion Syndrome C2931338
No
Different transmission
Body System
46 Xx Disorder Of Sex Development Induced By Maternal Derived Androgen C5680197
reproductive
3q13 Microdeletion Syndrome C2931338
congenital
Same/different system
Category
46 Xx Disorder Of Sex Development Induced By Maternal Derived Androgen C5680197
endocrine
3q13 Microdeletion Syndrome C2931338
genetic
Different category
Bottom line
46-xx-disorder-of-sex-development-induced-by-maternal-derived-androgen-C5680197 and 3q13-microdeletion-syndrome-C2931338 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 46 Xx Disorder Of Sex Development Induced By Maternal Derived Androgen C5680197 | 3q13 Microdeletion Syndrome C2931338 | Discriminating power |
|---|---|---|---|
| Genital development | Atypical genital development in an XX baby, ranging from mild to severe. | Genital findings are not the defining feature in the supplied description. | High |
| Development | Developmental delay is not established as a core feature. | Associated with developmental delay and intellectual disability. | High |
| Cause | Attributed to androgens from the pregnant person reaching the fetus. | Caused by missing chromosomal material at 3q13. | High |
When to favor each condition
Choose 46 Xx Disorder Of Sex Development Induced By Maternal Derived Androgen C5680197 when
XX newborn with atypical genitalia and relevant maternal androgen exposure
This pattern fits the described endocrine mechanism better than a microdeletion.
Moderate
46,XX karyotype without detected 3q13 deletion
A normal targeted genetic result makes the microdeletion diagnosis less likely.
Moderate
Main concern is genital development rather than syndromic delay
The supplied description centers on reproductive and endocrine effects.
Low
Choose 3q13 Microdeletion Syndrome C2931338 when
Developmental delay with a confirmed 3q13 deletion
Detection of missing 3q13 material directly supports this genetic diagnosis.
High
Intellectual disability and variable congenital features
These associations match the supplied syndrome description.
Moderate
No maternal androgen history and unexplained congenital findings
A chromosomal evaluation is more relevant than assuming androgen exposure.
Moderate
How key tests differ
| Test | 46 Xx Disorder Of Sex Development Induced By Maternal Derived Androgen C5680197 | 3q13 Microdeletion Syndrome C2931338 | Interpretation |
|---|---|---|---|
| Karyotype | 46,XX supports the stated context but not the androgen source. | May appear normal if the deletion is too small to see. | Karyotype alone cannot distinguish these diagnoses reliably. |
| Chromosomal microarray | A 3q13 deletion is not expected from the supplied mechanism. | May identify missing material at 3q13. | A confirmed deletion supports the right diagnosis; its absence needs specialist review. |
| Endocrine assessment | May investigate androgen exposure, but no cutoff is established here. | No characteristic endocrine result is established in the source. | An abnormal hormone result is not itself a complete diagnosis. |
Prognosis comparison
46 Xx Disorder Of Sex Development Induced By Maternal Derived Androgen C5680197
- Outcome
- Long-term outcome is variable and not quantified in the supplied data.
- Factors
- Degree of androgen effect, associated findings, and specialist care may influence course.
3q13 Microdeletion Syndrome C2931338
- Outcome
- A chronic course with developmental needs is described, but prognosis is not established.
- Factors
- Deletion findings, congenital anomalies, and developmental support may matter.
Time frame: Both may require follow-up beyond infancy; exact timelines are unavailable.
Confirmed etiology, associated anomalies, and access to coordinated care are key.
Complications comparison
| Complication | Presentation |
|---|---|
| Associated clinical burden | Concerns center on atypical genital development and endocrine care. Concerns include developmental delay, disability, and congenital features. Individual complications are variable and not fully defined here. |
| Need for procedures | Hormone or surgical management may be considered by specialists. Care may address developmental and congenital needs rather than genital surgery. No procedure, dose, or indication should be inferred from these data. |
| Family and psychosocial impact | Families may face sensitive decisions about sex development and care. Families may need long-term developmental and educational support. Support needs differ, but comparative outcomes are not established. |
Patient education highlights
- HighDiagnostic boundaries
An abnormal genital finding, hormone result, or genetic test needs clinician correlation before a diagnosis is made.
- HighDifferent tests
Endocrine tests and chromosomal microarray answer different questions and may both be relevant.
- MediumCare team
Genetics, endocrine, developmental, surgical, and psychosocial specialists may contribute as individually appropriate.